US Health Outcomes & Epidemiology, GSK, Philadelphia, PA, United States.
Health Preference Assessment Group, RTI Health Solutions, Research Triangle Park, NC, United States.
Expert Rev Vaccines. 2021 Jun;20(6):729-741. doi: 10.1080/14760584.2021.1910502. Epub 2021 Jul 22.
Most adults, and disproportionately fewer African-Americans, have not received herpes zoster (HZ) vaccination despite current recommendations. This study (GSK study identifiers: 208677/HO-17-18066) assessed HZ vaccination preferences among adults aged ≥ 50 years.
In this discrete choice experiment, respondents chose among a 'no vaccine' option and two HZ vaccine profiles, characterized by seven attributes, in a series of choice questions. Random-parameters logit results were used to predict likely vaccine uptake. Subgroup and latent class analysis of African-American's preferences were performed.
The preference weight for choosing HZ vaccines over no vaccine was statistically significant among the 1,454 respondents (71.9% whites; 25.2% African-Americans). Out-of-pocket (OOP) cost and vaccine effectiveness (VE) were the most important attributes. The African-American and the non-African-American subgroups had statistically significant differences in preferences (χ = 59.91, p < 0.001), mainly driven by OOP cost and VE. Latent class analysis identified three groups of African-American respondents with systematically different preferences; two comprised likely-vaccinators, with one being more cost sensitive at lower price thresholds, and one likely non-vaccinators.
For all respondents, HZ vaccine choices were most sensitive to total OOP cost, followed by VE.
尽管目前有相关建议，但大多数成年人（尤其是非裔美国人）并未接种带状疱疹（HZ）疫苗。本研究（GSK 研究标识符：208677/HO-17-18066）评估了≥50 岁成年人对 HZ 疫苗接种的偏好。
在这项离散选择实验中，受访者在“无疫苗”选项和两种 HZ 疫苗方案之间进行选择，这两种疫苗方案由七个属性来描述，受访者在一系列选择题中进行选择。使用随机参数对数模型结果预测疫苗接种的可能性。对非裔美国人的偏好进行了亚组和潜在类别分析。
在 1454 名受访者（71.9%为白人；25.2%为非裔美国人）中，选择 HZ 疫苗而非无疫苗的偏好权重具有统计学意义。自付费用（OOP）和疫苗效力（VE）是最重要的属性。非裔美国人和非非裔美国人亚组在偏好方面存在统计学上的显著差异（χ²=59.91，p<0.001），主要由 OOP 成本和 VE 驱动。潜在类别分析确定了三组具有系统差异偏好的非裔美国受访者；两组可能的接种者，其中一组在较低价格阈值下对成本更为敏感，另一组可能的非接种者。
对于所有受访者，HZ 疫苗的选择最敏感于总 OOP 成本，其次是 VE。
